• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Pembrolizuab Monotherapy Extended Survival in Advanced Lung Cancer

  • in AJO · Audio · Oncology
  • — 8 Jun, 2018
Lung Cancer
Gilberto Lopes
Pembrolizuab Monotherapy Extended Survival in Advanced Lung Cancer
AudioMedica News
Pembrolizuab Monotherapy Extended Survival in Advanced Lung Cancer
Pembrolizuab Monotherapy Extended Survival in Advanced Lung Cancer
00:00 / 14:00 mins
Apple Podcasts Spotify Stitcher
RSS Feed
Share
Link
Embed
//-->//>' class="input-embed input-embed-3618"/>

Subscribe: Apple Podcasts | Spotify | Stitcher

CHICAGO, IL—Patients whose non-small cell lung cancers (NSCLC) expressed more than one per cent of the programmed death ligand-1 (PD-L1) tumor proportion score (TPS) lived longer when treated with the anti programmed death 1 (PD-1) antibody pembrolizumab than a control group of patients receiving platinum-based chemotherapy in the open-label, phase three KEYNOTE-042 study reported at the American Society of Clinical Oncology (ASCO) annual meeting plenary session.  https://meetinglibrary.asco.org/record/165950/abstract

Better survival

Principal author of the study, Gilberto Lopes MD, Associate Professor of Clinical Medicine at the University of Miami’s Sylvester Comprehensive Cancer Center tells the Audio Journal of Onclogy patients treated with pebrolizumab monotherapy lived a median of four to eight months longer than those who received chemotherapy and had fewer severe side effects than with chemotherapy (18 per cent as compared with 41 per cent).

Pembrolizuab Monotherapy Extended Survival in Advanced Lung Cancer

John Heymach

You may also like...

  • Audio Journal of Oncology 13.3, April 2005 Audio Journal of Oncology 13.3, April 2005 6 Apr, 2005
  • Abdenour Nabid Androgen blockade: 18 as good as 36 months in radiotherapy-treated prostate cancer 24 Mar, 2013
  • Early Lung Cancer Responds to Preoperative Nivolumab Early Lung Cancer Responds to Preoperative Nivolumab 17 Nov, 2016
  • Audio Journal of Oncology in Advance – December 1st, 2006 Audio Journal of Oncology in Advance – December 1st, 2006 1 Dec, 2006

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Radiotherapy Cuts BRCA-Associated Contralateral Breast Cancer Risk
  • Next story Gender Disparity in Head and Neck Cancer Treatment and Outcomes
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Pembrolizumab: No Survival Gains Second Line In…
    • Microbiome Diversity Key To Survival After…
    • Gender Disparity in Head and Neck Cancer Treatment…
    • Can Initial Radiotherapy Improve Survival with…
  • Home
  • Oncology
  • AJO
  • Pembrolizuab Monotherapy Extended Survival in Advanced Lung Cancer

© COPYRIGHT 2020 AUDIOMEDICA.COM.